Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This symposium reported that DNA damage accumulation in aging stem cells affects genome integrity, highlighting novel mechanisms like Bmi1's role in DNA repair and the involvement of BATF in lymphoid differentiation.

This study found that deleting the Mad2l1 gene in mice leads to rapid onset of acute lymphoblastic leukemia and liver cancer due to induced chromosomal instability.

In this study, researchers using multistate modeling reported that patients with psoriasis treated with brodalumab had a higher probability of achieving and maintaining a therapeutic response compared to those treated with ustekinumab over 52 weeks, based on absolute PASI measurements.

The authors discussed that SOCS1 and SOCS3's inhibition of JAKs plays a significant role in the development of JAK inhibitor drugs for skin inflammatory diseases and malignancies.

This study found that FRβ knockout mice exhibited autoimmune symptoms and slower tumor growth compared to wild type mice, suggesting that the FRβ receptor may play a role in regulating immune responses in tumors and autoimmune conditions.

Hair graying may help prevent cancer by protecting stem cells.

This review discusses genome maintenance mechanisms critical for preventing age-related diseases by preserving stem and progenitor cell potential, but reports no new empirical findings.

This review discusses the characteristics and management of cutaneous immune-related adverse events from immune checkpoint inhibitors and notes their potential association with a favorable cancer treatment response.

This article compares the immunology of cancer and the placenta and suggests that immunotherapy for pregnant cancer patients could be feasible with careful exploration, though no new clinical results are reported.

This case report describes the first instance of eosinophilic folliculitis of the scalp occurring during nivolumab therapy, which responded partially to topical steroids and cream but did not require stopping the treatment.

This study found that engineered high-affinity soluble CD200R agonists, including ARQ-234, showed superior efficacy in reducing immune responses in various preclinical models of inflammatory conditions, suggesting potential as a therapeutic for atopic dermatitis and other related diseases.

This case report describes the first known occurrence of alopecia areata associated with cemiplimab, an anti-PD1 drug, in a patient with a positive cancer treatment response.

This review discusses the range of cutaneous immune-related adverse events induced by immune checkpoint inhibitors and the proposed mechanisms underlying these skin reactions, but reports no new clinical results.

In this study, pre-treatment with 5-α-reductase inhibitors (finasteride/dutasteride) in patients with metastatic renal cell carcinoma was associated with better immune checkpoint inhibitor effectiveness and improved progression-free and overall survival, without increasing severe side effects.

In this case report, a 77-year-old woman developed alopecia areata after discontinuing cemiplimab treatment for metastatic cutaneous squamous cell carcinoma, suggesting an immune-related adverse effect potentially linked to systemic immune activation.

This study suggests that CD8+ cytotoxic T lymphocytes play a crucial role in the development of alopecia areata, based on observations in rodent models that mimic human autoimmune disease.

This study found that sebaceous gland-derived cutaneous adnexal carcinomas exhibited the highest frequency of genomic alterations compared to other tumor types.

This review discusses the characteristics and treatment recommendations for skin-related adverse effects from immune checkpoint inhibitors in cancer treatment, and notes an observed association with favorable oncology outcomes that requires careful interpretation.

This case study reports a rare instance of pembrolizumab-induced eyelash trichomegaly in a 63-year-old male patient, highlighting the importance for clinicians to be aware of such uncommon adverse effects to manage patient treatment effectively.

In this case study, a 65-year-old male with hepatocellular carcinoma treated with the PD-1 inhibitor Sintilimab developed alopecia universalis alongside significant tumor regression and complete remission, highlighting a rare immune-related adverse event with effective anti-tumor outcomes.

This review discusses the challenges and opportunities in targeting the hedgehog pathway for aggressive cancers, emphasizing the complexities of treatment resistance, immune response, and the potential of combining immune checkpoint inhibitors with hedgehog pathway inhibitors, but reports no new clinical results.

This study concludes that combining chemotherapy with immune checkpoint inhibitors is additive rather than synergistic in terms of adverse events for advanced non-small cell lung cancer patients.

In this study, 37.5% of patients with nodal or metastatic cutaneous melanoma treated with immune checkpoint inhibitors developed skin adverse events, primarily low-grade rashes, vitiligo, and other dermatological symptoms, occurring mainly after 10 weeks of treatment.

This review highlights the promising potential of using nanomedicine-based immunotherapy in tissue regeneration, detailing recent advances in nanocomposite biomaterials and the modulation of immune responses to create optimal environments for tissue repair.

This study highlights that biological therapy, which stimulates the immune system through various methods like cytokine injections and immune checkpoint inhibition, shows promise for treating melanoma based on laboratory and clinical studies.

In this study, researchers presented a protocol for generating planar skin organoids from human induced pluripotent stem cells, which include hair follicles and other skin structures, offering a relevant in vitro model for investigating skin physiology, pathogen interactions, and drug responses.

This review discusses recent advances in understanding Merkel cell carcinoma biology, including the development of genetically-engineered mouse models and potential therapeutic targets, but reports no new clinical results.

This paper proposes a model integrating regulatory T cells and mesenchymal stem/stromal cells to enhance understanding of peripheral immune tolerance, suggesting their combined roles in immune regulation, autoimmunity pathophysiology, and potential MSC-based therapies.

This review summarizes recent discoveries about how tissue-resident stem cells interact with their environments during normal conditions and after injury, without reporting new results.

Hair shaft miniaturization leads to hair follicle stem cell loss, suggesting Piezo1 as a potential treatment target.